Table 1. Diagnosis and JAK2 V617F... | American Society of Hematology

Table 1.

Diagnosis and JAK2V617F mutational status of 1182 patients with a spectrum of myeloid disorders

		Mayo patients					Harvard patients
	N	No. of patients	JAK2V617F positive, no. (%)	MPL515L or -515K positive, no. (%)	No. of patients	JAK2V617F positive, no. (%)	MPL515L or -515K positive, no. (%)
All patients	1182	735	252	13	447	335	7
MMM	290	198	106 (54)	8 (4)	92	46 (50)	5 (5)
De novo	NA	159	75	8	NA	NA	4
After ET	NA	10	8	0	NA	NA	1
After PV	NA	29	23	0	NA	NA	n/a
ET	318	167	76 (46)	2 (1)	151	106 (70)	2 (1)
PV	242	38	38 (100)	0	204	183 (90)	0
AML	126	126	29 (23)	3 (2)	0	n/a	n/a
With antecedent MPD	NA	37	23	3	0	n/a	n/a
MDS	88	88	0	0	0	n/a	n/a
CMML	118	118	3 (3)	0	0	n/a	n/a

		Mayo patients					Harvard patients
	N	No. of patients	JAK2V617F positive, no. (%)	MPL515L or -515K positive, no. (%)	No. of patients	JAK2V617F positive, no. (%)	MPL515L or -515K positive, no. (%)
All patients	1182	735	252	13	447	335	7
MMM	290	198	106 (54)	8 (4)	92	46 (50)	5 (5)
De novo	NA	159	75	8	NA	NA	4
After ET	NA	10	8	0	NA	NA	1
After PV	NA	29	23	0	NA	NA	n/a
ET	318	167	76 (46)	2 (1)	151	106 (70)	2 (1)
PV	242	38	38 (100)	0	204	183 (90)	0
AML	126	126	29 (23)	3 (2)	0	n/a	n/a
With antecedent MPD	NA	37	23	3	0	n/a	n/a
MDS	88	88	0	0	0	n/a	n/a
CMML	118	118	3 (3)	0	0	n/a	n/a

MMM indicates myelofibrosis with myeloid metaplasia; ET, essential thrombocythemia; PV, polycythemia vera; AML, acute myeloid leukemia; MPD, myeloproliferative disorder; MDS, myelodysplastic syndrome; CMML, chronic myelomonocytic leukemia; NA, accurate subclassification not available because of study design; and n/a, not applicable

View Large

This Feature Is Available To Subscribers Only